Gene module is target-rich environment for Alzheimer's pathology, cognitive decline
A team of NIA-supported researchers, as part of the
Accelerating Medicines Partnership for Alzheimer's disease (AMP-AD) Target
Discovery and Preclinical Validation consortium has zeroed in on several
potential therapeutic targets from a cluster of genes associated with
Alzheimer’s disease brain pathology and cognitive decline.
#Alzheimers2018 is scheduled to be held in December 03-04, 2018 at Madrid, Spain.
To know more download our brochure via: https://bit.ly/2Ld1keT
The finding is an important milestone for the AMP-AD program
and Alzheimer’s disease research in general, as it demonstrates the power of
systems-based modelling approaches to identify causal associations between
entire networks of genes and various pathologic and/or clinical traits for
Alzheimer’s disease. Known as gene module-trait network (MTN) analysis, this
technique gives a more holistic view of molecular targets than traditional
single gene associations, focusing on disease-relevant patterns of co-expressed
genes that can enable entire gene networks to be therapeutically modulated to
more robustly modify the disease process.
#Alzheimers2018 is scheduled to be held in December 03-04, 2018 at Madrid, Spain.
To know more download our brochure via: https://bit.ly/2Ld1keT
Comments
Post a Comment